Datasets:
OTAR3088
/
BioData-CellLine_annotated

Dataset card Data Studio Files
xet
Community
1
PMCID
string
Sentences
string
ner
list
PMC11718274
14.94 and 28.89 µg/ml) for 72 h. Fig. 10Regression lines and correlation coefficient between Y2O3NPs concentrations (7.47.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "14.94", "and", "28.89", "µg/ml", ")", "for", "72", "h.", "Fig.", "10Regression", "lines", "and", "correlation", "coefficient", "between", "Y2O3NPs", "concentrations", "(", "7.47", "." ] } ]
PMC10419319
Cell lysates were prepared using NP40 Cell Lysis Buffer (Invitrogen, Carlsbad, CA, USA), supplemented with Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, MA, USA).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Cell", "lysates", "were", "prepared", "using", "NP40", "Cell", "Lysis", "Buffer", "(", "Invitrogen", ",", "Carlsbad", ",", "CA", ",", "USA", ")", ",", "supplemented", "with", "Halt", "™", "Protease", "and", "Phosphatase", "Inhibitor", "Cocktail", "(", "Thermo", "Fisher", "Scientific", ",", "Waltham", ",", "MA", ",", "USA", ")", "." ] } ]
PMC9164404
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) kit were purchased from Roche (Basel, Switzerland).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Terminal", "deoxynucleotidyl", "transferase", "dUTP", "nick", "end", "labeling", "(", "TUNEL", ")", "kit", "were", "purchased", "from", "Roche", "(", "Basel", ",", "Switzerland", ")", "." ] } ]
PMC9429973
After three cycles of iFCG, 39/45 (87%) pts achieved marrow U-MRD.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "After", "three", "cycles", "of", "iFCG", ",", "39/45", "(", "87", "%", ")", "pts", "achieved", "marrow", "U-MRD", "." ] } ]
PMC9429973
Methods: We analyzed 24 specimen of pediatric AML, MPAL and bilineage leukemia patients by OGM starting from stored frozen material (bone marrow, peripheral blood) obtained at initial diagnosis.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Methods", ":", "We", "analyzed", "24", "specimen", "of", "pediatric", "AML", ",", "MPAL", "and", "bilineage", "leukemia", "patients", "by", "OGM", "starting", "from", "stored", "frozen", "material", "(", "bone", "marrow", ",", "peripheral", "blood", ")", "obtained", "at", "initial", "diagnosis", "." ] } ]
PMC6160470
Selected concentration enabled testing without any toxic effect on the cells, and is in accordance with previously published data for verapamil (first generation P-gp inhibitor).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Selected", "concentration", "enabled", "testing", "without", "any", "toxic", "effect", "on", "the", "cells", ",", "and", "is", "in", "accordance", "with", "previously", "published", "data", "for", "verapamil", "(", "first", "generation", "P-gp", "inhibitor", ")", "." ] } ]
PMC9429973
ROS play a pivotal role in inflammation-induced oxidative damage to cellular components including DNA, that leads to greater genomic instability and promotes cell transformation.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "ROS", "play", "a", "pivotal", "role", "in", "inflammation-induced", "oxidative", "damage", "to", "cellular", "components", "including", "DNA", ",", "that", "leads", "to", "greater", "genomic", "instability", "and", "promotes", "cell", "transformation", "." ] } ]
PMC8903741
Hence, we transfected a GFP-expressing gene to additional cells and used the GFP-expressing transfectants as a control for confirming the transfection efficiency and optimizing the G-418 concentration forantibody-expressing gene-transfected cells (Fig. 2).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Hence", ",", "we", "transfected", "a", "GFP-expressing", "gene", "to", "additional", "cells", "and", "used", "the", "GFP-expressing", "transfectants", "as", "a", "control", "for", "confirming", "the", "transfection", "efficiency", "and", "optimizing", "the", "G-418", "concentration", "forantibody-expressing", "gene-transfected", "cells", "(", "Fig.", "2", ")", "." ] } ]
PMC10919056
Drug sensitivity analysis indicated that the high-RS subgroup was more sensitive to afatinib, erlotinib, rapamycin, and sorafenib, while the low-RS subgroup exhibited greater sensitivity to axitinib, which is conducive to the development of individualized chemotherapy regimens for patients with advanced ccRCC.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Drug", "sensitivity", "analysis", "indicated", "that", "the", "high-RS", "subgroup", "was", "more", "sensitive", "to", "afatinib", ",", "erlotinib", ",", "rapamycin", ",", "and", "sorafenib", ",", "while", "the", "low-RS", "subgroup", "exhibited", "greater", "sensitivity", "to", "axitinib", ",", "which", "is", "conducive", "to", "the", "development", "of", "individualized", "chemotherapy", "regimens", "for", "patients", "with", "advanced", "ccRCC", "." ] } ]
PMC11659921
Cells from different treatments were cultured in 96‐well plates at a density of 1 × 103 cells per well.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Cells", "from", "different", "treatments", "were", "cultured", "in", "96‐well", "plates", "at", "a", "density", "of", "1", "×", "103", "cells", "per", "well", "." ] } ]
PMC11711663
In the medical field, a Pearson’s score of 0.7 suggests a moderate agreement between two features based on previous studies.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "In", "the", "medical", "field", ",", "a", "Pearson", "’s", "score", "of", "0.7", "suggests", "a", "moderate", "agreement", "between", "two", "features", "based", "on", "previous", "studies", "." ] } ]
PMC11565047
The Kallisto tool was used for the pseudo-alignment of the trimmed sequences to the Gencode v27 human reference transcriptome, also on default parameters .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "Kallisto", "tool", "was", "used", "for", "the", "pseudo-alignment", "of", "the", "trimmed", "sequences", "to", "the", "Gencode", "v27", "human", "reference", "transcriptome", ",", "also", "on", "default", "parameters", "." ] } ]
PMC11592837
The Alu integrity index also increased gradually until 4 h in both cell types, with PBMCs displaying notably lower means without a statistically significant difference, while predominantly in Jurkat cells, a decrease was observed at later time points (Supplemental Figure S4C).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "Alu", "integrity", "index", "also", "increased", "gradually", "until", "4", "h", "in", "both", "cell", "types", ",", "with", "PBMCs", "displaying", "notably", "lower", "means", "without", "a", "statistically", "significant", "difference", ",", "while", "predominantly", "in", "Jurkat", "cells", ",", "a", "decrease", "was", "observed", "at", "later", "time", "points", "(", "Supplemental", "Figure", "S4C", ")", "." ] } ]
PMC11409031
Cell viability was measured by conducting the Cell Counting Kit-8 assay (Beyotime, China) in accordance with the instructions provided by the manufacturer.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Cell", "viability", "was", "measured", "by", "conducting", "the", "Cell", "Counting", "Kit-8", "assay", "(", "Beyotime", ",", "China", ")", "in", "accordance", "with", "the", "instructions", "provided", "by", "the", "manufacturer", "." ] } ]
PMC10376064
This dosage matched the one used in our previous experiments and was comparable to the dosage used in the treatment of multiple sclerosis patients (Data described in the pharmacological review application 204063Orig1s000 to the FDA by Paul C. Brown, (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000PharmR.pdf (accessed on 10 May 2023)).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "This", "dosage", "matched", "the", "one", "used", "in", "our", "previous", "experiments", "and", "was", "comparable", "to", "the", "dosage", "used", "in", "the", "treatment", "of", "multiple", "sclerosis", "patients", "(", "Data", "described", "in", "the", "pharmacological", "review", "application", "204063Orig1s000", "to", "the", "FDA", "by", "Paul", "C.", "Brown", ",", "(", "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000PharmR.pdf", "(", "accessed", "on", "10", "May", "2023", ")", ")", "." ] } ]
PMC10443665
Methotrexate concentration was increased by 4 folds after every full growth recovery.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Methotrexate", "concentration", "was", "increased", "by", "4", "folds", "after", "every", "full", "growth", "recovery", "." ] } ]
PMC9429973
Summary/Conclusion: Our single-center observations confirmed previous publications that BAALC gene overexpression is a frequent genetic abnormality in AML patients.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Summary/Conclusion", ":", "Our", "single-center", "observations", "confirmed", "previous", "publications", "that", "BAALC", "gene", "overexpression", "is", "a", "frequent", "genetic", "abnormality", "in", "AML", "patients", "." ] } ]
PMC11593031
Murine cancer cell lines are applied as a model system for human tumors, including NBs.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Murine", "cancer", "cell", "lines", "are", "applied", "as", "a", "model", "system", "for", "human", "tumors", ",", "including", "NBs", "." ] } ]
PMC11225860
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "authors", "declare", "that", "they", "have", "no", "known", "competing", "financial", "interests", "or", "personal", "relationships", "that", "could", "have", "appeared", "to", "influence", "the", "work", "reported", "in", "this", "paper", "." ] } ]
PMC10218459
CPP treatment was performed for 5 s. Each cell line was seeded with 2 × 10 cells in 200 µL of full medium and directly exposed to CPP in 6 wells of a 24-well plate.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "CPP", "treatment", "was", "performed", "for", "5", "s.", "Each", "cell", "line", "was", "seeded", "with", "2", "×", "10", "cells", "in", "200", "µL", "of", "full", "medium", "and", "directly", "exposed", "to", "CPP", "in", "6", "wells", "of", "a", "24-well", "plate", "." ] } ]
PMC8658661
Researchers are studying its molecular composition at the genomic, transcriptomic, and proteomic levels, each time confirming that the HepG2 is only partially similar to primary hepatocytes and cancer cells.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Researchers", "are", "studying", "its", "molecular", "composition", "at", "the", "genomic", ",", "transcriptomic", ",", "and", "proteomic", "levels", ",", "each", "time", "confirming", "that", "the", "HepG2", "is", "only", "partially", "similar", "to", "primary", "hepatocytes", "and", "cancer", "cells", "." ] } ]
PMC11611077
In the present study, effects of two types of promoters, i.e., EF1α and CMV, on the expression of prestin in CHO cells were investigated.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellLine", "O", "O", "O", "O" ], "tokens": [ "In", "the", "present", "study", ",", "effects", "of", "two", "types", "of", "promoters", ",", "i.e.", ",", "EF1α", "and", "CMV", ",", "on", "the", "expression", "of", "prestin", "in", "CHO", "cells", "were", "investigated", "." ] } ]
PMC11590005
Despite legal attempts at historical reparations, there is still a lot of inequality in Brazil and throughout Latin America between whites and non-whites, as well as gender inequality.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Despite", "legal", "attempts", "at", "historical", "reparations", ",", "there", "is", "still", "a", "lot", "of", "inequality", "in", "Brazil", "and", "throughout", "Latin", "America", "between", "whites", "and", "non-whites", ",", "as", "well", "as", "gender", "inequality", "." ] } ]
PMC11298021
Notably, this expression pattern closely resembled their expression levels in clinical samples (Fig. 1A), suggesting potential roles for these miRNAs in leukemia development.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Notably", ",", "this", "expression", "pattern", "closely", "resembled", "their", "expression", "levels", "in", "clinical", "samples", "(", "Fig.", "1A", ")", ",", "suggesting", "potential", "roles", "for", "these", "miRNAs", "in", "leukemia", "development", "." ] } ]
PMC10958426
We calculated the communication distance of a pathway by rankSimilarity function between normal and tumor sample in each patient.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "We", "calculated", "the", "communication", "distance", "of", "a", "pathway", "by", "rankSimilarity", "function", "between", "normal", "and", "tumor", "sample", "in", "each", "patient", "." ] } ]
PMC11190538
Using the GraphPad PRISM software, the 50 % cytotoxic concentrations (CC50) were determined from the mean dose-response curves.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Using", "the", "GraphPad", "PRISM", "software", ",", "the", "50", "%", "cytotoxic", "concentrations", "(", "CC50", ")", "were", "determined", "from", "the", "mean", "dose-response", "curves", "." ] } ]
PMC11697703
For dendritic analysis after miR-193b∼365 LoF in deep-layer neurons, we used an in vitro approach.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "For", "dendritic", "analysis", "after", "miR-193b∼365", "LoF", "in", "deep-layer", "neurons", ",", "we", "used", "an", "in", "vitro", "approach", "." ] } ]
PMC11737091
Standardized fragments per kilobase of transcript per million fragments mapped (FPKM) gene expression data profiles, genetic alteration landscapes, and clinical data were obtained from The Cancer Genome Atlas (TCGA) by using the R package TCGAbiolinks (v.2.24.3) .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Standardized", "fragments", "per", "kilobase", "of", "transcript", "per", "million", "fragments", "mapped", "(", "FPKM", ")", "gene", "expression", "data", "profiles", ",", "genetic", "alteration", "landscapes", ",", "and", "clinical", "data", "were", "obtained", "from", "The", "Cancer", "Genome", "Atlas", "(", "TCGA", ")", "by", "using", "the", "R", "package", "TCGAbiolinks", "(", "v.2.24.3", ")", "." ] } ]
PMC9596868
Combination of luteolin with MST-312 exhibited significantly increased cytotoxicity as compared to the compounds alone (Supplementary Fig. 4B–C).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Combination", "of", "luteolin", "with", "MST-312", "exhibited", "significantly", "increased", "cytotoxicity", "as", "compared", "to", "the", "compounds", "alone", "(", "Supplementary", "Fig.", "4B", "–", "C", ")", "." ] } ]
PMC11754436
The overall survival of the patients with OS was predicted by Kaplan-Meier survival analysis using the survival R package (Version 2.40–5, https://github.com/therneau/survival).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "overall", "survival", "of", "the", "patients", "with", "OS", "was", "predicted", "by", "Kaplan-Meier", "survival", "analysis", "using", "the", "survival", "R", "package", "(", "Version", "2.40–5", ",", "https://github.com/therneau/survival", ")", "." ] } ]
PMC10142392
Several studies have reported the successful use of multi-arm PCL-based nanoparticles for the delivery of various drugs, including anticancer agents, antibiotics, and anti-inflammatory agents .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Several", "studies", "have", "reported", "the", "successful", "use", "of", "multi-arm", "PCL-based", "nanoparticles", "for", "the", "delivery", "of", "various", "drugs", ",", "including", "anticancer", "agents", ",", "antibiotics", ",", "and", "anti-inflammatory", "agents", "." ] } ]
PMC9429973
However, the effects of G-CSF on the differentiation of MAITs to various subsets and the exertion of different effector functions remain to be further elucidated.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "However", ",", "the", "effects", "of", "G-CSF", "on", "the", "differentiation", "of", "MAITs", "to", "various", "subsets", "and", "the", "exertion", "of", "different", "effector", "functions", "remain", "to", "be", "further", "elucidated", "." ] } ]
PMC11519583
g Fluorescence intensity of SPiDER-βGal in MPs treated with the indicated siRNAs was monitored by flow cytometric analysis.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "g", "Fluorescence", "intensity", "of", "SPiDER-βGal", "in", "MPs", "treated", "with", "the", "indicated", "siRNAs", "was", "monitored", "by", "flow", "cytometric", "analysis", "." ] } ]
PMC8873393
This result supports the idea that mA modification of noncoding RNAs mainly regulates the post-transcriptional RNA metabolism including the transport, stability, and degradation of noncoding RNAs themselves.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "This", "result", "supports", "the", "idea", "that", "mA", "modification", "of", "noncoding", "RNAs", "mainly", "regulates", "the", "post-transcriptional", "RNA", "metabolism", "including", "the", "transport", ",", "stability", ",", "and", "degradation", "of", "noncoding", "RNAs", "themselves", "." ] } ]
PMC11656657
Overall-Survival (OS) of RD (ERMS) (D) and 143B (OS) (I) tumor-bearing NSG mice treated with NT T-cells (black line) or CAR.GD2 T-cells (blue and red respectively).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Overall-Survival", "(", "OS", ")", "of", "RD", "(", "ERMS", ")", "(", "D", ")", "and", "143B", "(", "OS", ")", "(", "I", ")", "tumor-bearing", "NSG", "mice", "treated", "with", "NT", "T-cells", "(", "black", "line", ")", "or", "CAR.GD2", "T-cells", "(", "blue", "and", "red", "respectively", ")", "." ] } ]
PMC11740399
T24 cells from human bladder metastatic cell carcinoma have a membrane composition well-suited for targeting bladder cancer.
[ { "tags": [ "B-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "T24", "cells", "from", "human", "bladder", "metastatic", "cell", "carcinoma", "have", "a", "membrane", "composition", "well-suited", "for", "targeting", "bladder", "cancer", "." ] } ]
PMC11252553
Ficoll-Hypaque solution and Red Blood Cell (RBC) lysis buffer (1X) were purchased from DNAbiotrch and Kiazist companies (Iran), respectively.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Ficoll-Hypaque", "solution", "and", "Red", "Blood", "Cell", "(", "RBC", ")", "lysis", "buffer", "(", "1X", ")", "were", "purchased", "from", "DNAbiotrch", "and", "Kiazist", "companies", "(", "Iran", ")", ",", "respectively", "." ] } ]
PMC9065483
Plot shows cell viability against log fold-change in viral titers of all compounds.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Plot", "shows", "cell", "viability", "against", "log", "fold-change", "in", "viral", "titers", "of", "all", "compounds", "." ] } ]
PMC9429973
Recent randomized trials (REACH2 and REACH3) demonstrated efficacy of the selective JAK1/2 inhibitor ruxolitinib (Ruxo) in steroid-refractory acute (aGvHD) and chronic GvHD (cGvHD) treatment (tr).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Recent", "randomized", "trials", "(", "REACH2", "and", "REACH3", ")", "demonstrated", "efficacy", "of", "the", "selective", "JAK1/2", "inhibitor", "ruxolitinib", "(", "Ruxo", ")", "in", "steroid-refractory", "acute", "(", "aGvHD", ")", "and", "chronic", "GvHD", "(", "cGvHD", ")", "treatment", "(", "tr", ")", "." ] } ]
PMC10538569
2 x 10 CEMss-CCR5-GPI-scFv X5 or AB65 cells were seeded in 800 µl complete RPMI 1640 in the upper chamber of 24-well transwell plates (Corning) and 1 X 10 HIV-1-captured iDCs in 1ml RPMI1640 were added at the bottom chamber.
[ { "tags": [ "O", "O", "O", "B-CellLine", "O", "O", "B-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "2", "x", "10", "CEMss-CCR5-GPI-scFv", "X5", "or", "AB65", "cells", "were", "seeded", "in", "800", "µl", "complete", "RPMI", "1640", "in", "the", "upper", "chamber", "of", "24-well", "transwell", "plates", "(", "Corning", ")", "and", "1", "X", "10", "HIV-1-captured", "iDCs", "in", "1ml", "RPMI1640", "were", "added", "at", "the", "bottom", "chamber", "." ] } ]
PMC11766309
Our study focused primarily on establishing YKT6 as a prognostic marker and its role in autophagy and immune modulation.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Our", "study", "focused", "primarily", "on", "establishing", "YKT6", "as", "a", "prognostic", "marker", "and", "its", "role", "in", "autophagy", "and", "immune", "modulation", "." ] } ]
PMC11087055
First, we apply a high-pass filter during the image preprocessing step to highlight the bright particles (fluorescently tagged cell) and minimize the background.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "First", ",", "we", "apply", "a", "high-pass", "filter", "during", "the", "image", "preprocessing", "step", "to", "highlight", "the", "bright", "particles", "(", "fluorescently", "tagged", "cell", ")", "and", "minimize", "the", "background", "." ] } ]
PMC10135767
The results showed that calcium signaling in RPMI 8226 cells firmly adhered to integrin α4β7-MAdCAM-1 and was effectively activated and positively regulated by the concentration of immobilized MAdCAM-1 and fluid shear stress.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "B-CellLine", "I-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "results", "showed", "that", "calcium", "signaling", "in", "RPMI", "8226", "cells", "firmly", "adhered", "to", "integrin", "α4β7-MAdCAM-1", "and", "was", "effectively", "activated", "and", "positively", "regulated", "by", "the", "concentration", "of", "immobilized", "MAdCAM-1", "and", "fluid", "shear", "stress", "." ] } ]
PMC7504302
Furthermore, TP53, PIK3CA, and KDR mutations were clinically associated with significantly reduced overall survival .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Furthermore", ",", "TP53", ",", "PIK3CA", ",", "and", "KDR", "mutations", "were", "clinically", "associated", "with", "significantly", "reduced", "overall", "survival", "." ] } ]
PMC9031474
Synthetic modification of natural products provides a valuable strategy for increasing pharmacological properties .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Synthetic", "modification", "of", "natural", "products", "provides", "a", "valuable", "strategy", "for", "increasing", "pharmacological", "properties", "." ] } ]
PMC9429973
We used nonparametric statistics methods calculated in the Statistica 10.0.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "We", "used", "nonparametric", "statistics", "methods", "calculated", "in", "the", "Statistica", "10.0", "." ] } ]
PMC10203589
The extracellular domain can bind to heparin or heparin sulfate (HS) proteoglycans, and it has been shown that this tight binding not only enhances FGF-FGFR complex binding, but also interacts with neighboring FGF-FGFR complexes to promote FGFR dimerization (193).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "extracellular", "domain", "can", "bind", "to", "heparin", "or", "heparin", "sulfate", "(", "HS", ")", "proteoglycans", ",", "and", "it", "has", "been", "shown", "that", "this", "tight", "binding", "not", "only", "enhances", "FGF-FGFR", "complex", "binding", ",", "but", "also", "interacts", "with", "neighboring", "FGF-FGFR", "complexes", "to", "promote", "FGFR", "dimerization", "(", "193", ")", "." ] } ]
PMC11684269
In certain contexts, albeit specific knockout of CPT1A in T cells, the CPT1A inhibitor, etomoxir still exhibits the capacity of modulating Treg cell, as well as CD8 memory T cell differentiation, suggesting the existence of alternative bioenergetic fueling mechanism beyond FAO (55).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "In", "certain", "contexts", ",", "albeit", "specific", "knockout", "of", "CPT1A", "in", "T", "cells", ",", "the", "CPT1A", "inhibitor", ",", "etomoxir", "still", "exhibits", "the", "capacity", "of", "modulating", "Treg", "cell", ",", "as", "well", "as", "CD8", "memory", "T", "cell", "differentiation", ",", "suggesting", "the", "existence", "of", "alternative", "bioenergetic", "fueling", "mechanism", "beyond", "FAO", "(", "55", ")", "." ] } ]
PMC8382973
To control for potential variants, RL and CVL samples were randomly chosen as follows (1): T0 (baseline): CM-01 (NWR1), CM-02 (NWR2), CF-01 (NWF1), and CF-02 (NWF2); (2) T14 (after 14 days administration): PBS group: PBSM1, PBSM2, PBSF25, and PBSF26; gel group: GELM3, GELM4, GELF27, and GELF28; SFT gel high-dose group: SFTHM5, SFTHM6, SFTHF29, and SFTHF30; SFT gel low-dose group: SFTLM7, SFTLM8, SFTLF31, and SFTLF32; 2P23 gel high-dose group: 2P23HM9, 2P23HM10, 2P23HF33, and 2P23HF34; 2P23 gel low-dose group: 2P23LM11, 2P23LM12, 2P23LF35, and 2P23LF36; LP80 gel high-dose group: LP80HM13, LP80HM14, LP80HF37, and LP80HF38; LP80 gel low-dose group: LP80LM15, LP80LM16, LP80LF39, and LP80LF40; LP98 gel high-dose group: LP98HM17, LP98HM18, LP98HF41, and LP98HF42; LP98 gel low-dose group: LP98LM19, LP98LM20, LP98LF43, and LP98LF44; Triton X-100 group: Triton100M21, Triton100M22, Triton100F45, and Triton100F46; SDS group: SDSM23, SDSM24, SDSF47, and SDSF48.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "To", "control", "for", "potential", "variants", ",", "RL", "and", "CVL", "samples", "were", "randomly", "chosen", "as", "follows", "(", "1", "):", "T0", "(", "baseline", "):", "CM-01", "(", "NWR1", ")", ",", "CM-02", "(", "NWR2", ")", ",", "CF-01", "(", "NWF1", ")", ",", "and", "CF-02", "(", "NWF2", ")", ";", "(", "2", ")", "T14", "(", "after", "14", "days", "administration", "):", "PBS", "group", ":", "PBSM1", ",", "PBSM2", ",", "PBSF25", ",", "and", "PBSF26", ";", "gel", "group", ":", "GELM3", ",", "GELM4", ",", "GELF27", ",", "and", "GELF28", ";", "SFT", "gel", "high-dose", "group", ":", "SFTHM5", ",", "SFTHM6", ",", "SFTHF29", ",", "and", "SFTHF30", ";", "SFT", "gel", "low-dose", "group", ":", "SFTLM7", ",", "SFTLM8", ",", "SFTLF31", ",", "and", "SFTLF32", ";", "2P23", "gel", "high-dose", "group", ":", "2P23HM9", ",", "2P23HM10", ",", "2P23HF33", ",", "and", "2P23HF34", ";", "2P23", "gel", "low-dose", "group", ":", "2P23LM11", ",", "2P23LM12", ",", "2P23LF35", ",", "and", "2P23LF36", ";", "LP80", "gel", "high-dose", "group", ":", "LP80HM13", ",", "LP80HM14", ",", "LP80HF37", ",", "and", "LP80HF38", ";", "LP80", "gel", "low-dose", "group", ":", "LP80LM15", ",", "LP80LM16", ",", "LP80LF39", ",", "and", "LP80LF40", ";", "LP98", "gel", "high-dose", "group", ":", "LP98HM17", ",", "LP98HM18", ",", "LP98HF41", ",", "and", "LP98HF42", ";", "LP98", "gel", "low-dose", "group", ":", "LP98LM19", ",", "LP98LM20", ",", "LP98LF43", ",", "and", "LP98LF44", ";", "Triton", "X-100", "group", ":", "Triton100M21", ",", "Triton100M22", ",", "Triton100F45", ",", "and", "Triton100F46", ";", "SDS", "group", ":", "SDSM23", ",", "SDSM24", ",", "SDSF47", ",", "and", "SDSF48", "." ] } ]
PMC11597291
GNR-4arm PEG exhibited enhanced colloidal stability in cell culture media for up to 48 h, while GO-4arm PEG was stable for up to 24 h. In comparison, GNR-4arm PEG expressed superior inhibition effects on tumor spheroid adhesion than GO-4arm PEG.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "GNR-4arm", "PEG", "exhibited", "enhanced", "colloidal", "stability", "in", "cell", "culture", "media", "for", "up", "to", "48", "h", ",", "while", "GO-4arm", "PEG", "was", "stable", "for", "up", "to", "24", "h.", "In", "comparison", ",", "GNR-4arm", "PEG", "expressed", "superior", "inhibition", "effects", "on", "tumor", "spheroid", "adhesion", "than", "GO-4arm", "PEG", "." ] } ]
PMC9429973
Study endpoints include manufacture feasibility, grade 3-5 toxicity and remission rates at 1 and 3 months.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Study", "endpoints", "include", "manufacture", "feasibility", ",", "grade", "3", "-", "5", "toxicity", "and", "remission", "rates", "at", "1", "and", "3", "months", "." ] } ]
PMC11789597
Next, we determined whether targeting CAV1 enhances the cytotoxicity of NK cells derived from MM patients.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Next", ",", "we", "determined", "whether", "targeting", "CAV1", "enhances", "the", "cytotoxicity", "of", "NK", "cells", "derived", "from", "MM", "patients", "." ] } ]
PMC11705862
Nevertheless, our cell culture studies demonstrating increased p-tau accumulation when all isoforms of CD59 are silenced support the idea that IRIS reduction, at least in vitro, is an event upstream to p-tau accumulation.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Nevertheless", ",", "our", "cell", "culture", "studies", "demonstrating", "increased", "p-tau", "accumulation", "when", "all", "isoforms", "of", "CD59", "are", "silenced", "support", "the", "idea", "that", "IRIS", "reduction", ",", "at", "least", "in", "vitro", ",", "is", "an", "event", "upstream", "to", "p-tau", "accumulation", "." ] } ]
PMC11078693
The stained cells can be stored for up to 3 weeks.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "stained", "cells", "can", "be", "stored", "for", "up", "to", "3", "weeks", "." ] } ]
PMC11088135
The results showed that lncRNA NUTM2A-AS1-siRNA significantly reduced the expression of lncRNA NUTM2A-AS1 in U251 cells (Fig. 3A).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellLine", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "results", "showed", "that", "lncRNA", "NUTM2A-AS1-siRNA", "significantly", "reduced", "the", "expression", "of", "lncRNA", "NUTM2A-AS1", "in", "U251", "cells", "(", "Fig.", "3A", ")", "." ] } ]
PMC11277157
Amplicon size was confirmed to be 196 nt and 376 nt for β-actin and PARK7, respectively.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Amplicon", "size", "was", "confirmed", "to", "be", "196", "nt", "and", "376", "nt", "for", "β-actin", "and", "PARK7", ",", "respectively", "." ] } ]
PMC11762280
More experiments are still needed to verify our speculation.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "More", "experiments", "are", "still", "needed", "to", "verify", "our", "speculation", "." ] } ]
PMC9429973
She completed 6 cycles.
[ { "tags": [ "O", "O", "O", "O", "O" ], "tokens": [ "She", "completed", "6", "cycles", "." ] } ]
PMC5963610
Furthermore, NGcGM3/VSSP vaccine, but not the mAb 7A7 decreased the expression of NGcGM3 (Figure 2D), uPAR (Figure 2E) and α5β1 integrin (Figure 2F) in contrast with the control group.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Furthermore", ",", "NGcGM3/VSSP", "vaccine", ",", "but", "not", "the", "mAb", "7A7", "decreased", "the", "expression", "of", "NGcGM3", "(", "Figure", "2D", ")", ",", "uPAR", "(", "Figure", "2E", ")", "and", "α5β1", "integrin", "(", "Figure", "2F", ")", "in", "contrast", "with", "the", "control", "group", "." ] } ]
PMC11529598
MicroRNAs (miRNAs) are a short single-strand non-coding RNAs with about 22 nucleotides in length.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "MicroRNAs", "(", "miRNAs", ")", "are", "a", "short", "single-strand", "non-coding", "RNAs", "with", "about", "22", "nucleotides", "in", "length", "." ] } ]
PMC11628309
These findings show how BE (2)-M17 cells can be employed to understand additional molecular mechanisms in PD pathology, advancing our understanding of cellular organelle dynamics in dopaminergic neurodegeneration.
[ { "tags": [ "O", "O", "O", "O", "B-CellLine", "I-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "These", "findings", "show", "how", "BE", "(2)-M17", "cells", "can", "be", "employed", "to", "understand", "additional", "molecular", "mechanisms", "in", "PD", "pathology", ",", "advancing", "our", "understanding", "of", "cellular", "organelle", "dynamics", "in", "dopaminergic", "neurodegeneration", "." ] } ]
PMC11656048
p < 0.05, **p < 0.01, ***p < 0.001.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "p", "<", "0.05", ",", "*", "*", "p", "<", "0.01", ",", "*", "*", "*", "p", "<", "0.001", "." ] } ]
PMC11209164
Once tumor volumes reached 1500 mm, the mice were euthanized, and relevant tissues were extracted.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Once", "tumor", "volumes", "reached", "1500", "mm", ",", "the", "mice", "were", "euthanized", ",", "and", "relevant", "tissues", "were", "extracted", "." ] } ]
PMC9429973
Mitapivat (AG-348) is a first-in-class, oral, allosteric activator of PKR which has demonstrated significant improvements in Hb, markers of hemolysis and hematopoiesis, and reduction in disease burden in pts who were not regularly transfused (ACTIVATE, NCT03548220) and significant reduction in transfusion burden in pts who were regularly transfused (ACTIVATE-T, NCT03559699) with PK deficiency.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Mitapivat", "(", "AG-348", ")", "is", "a", "first-in-class", ",", "oral", ",", "allosteric", "activator", "of", "PKR", "which", "has", "demonstrated", "significant", "improvements", "in", "Hb", ",", "markers", "of", "hemolysis", "and", "hematopoiesis", ",", "and", "reduction", "in", "disease", "burden", "in", "pts", "who", "were", "not", "regularly", "transfused", "(", "ACTIVATE", ",", "NCT03548220", ")", "and", "significant", "reduction", "in", "transfusion", "burden", "in", "pts", "who", "were", "regularly", "transfused", "(", "ACTIVATE-T", ",", "NCT03559699", ")", "with", "PK", "deficiency", "." ] } ]
PMC10470467
Here, the reason why we adopted the random survival forest algorithm rather than LASSO regression analysis is as follows: First, VIMP and MD, as two tested quantitative indicators, could be used for key gene identification.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Here", ",", "the", "reason", "why", "we", "adopted", "the", "random", "survival", "forest", "algorithm", "rather", "than", "LASSO", "regression", "analysis", "is", "as", "follows", ":", "First", ",", "VIMP", "and", "MD", ",", "as", "two", "tested", "quantitative", "indicators", ",", "could", "be", "used", "for", "key", "gene", "identification", "." ] } ]
PMC10362265
We computed average fluctuations of the human complex using two replicates of the human crystal complex (7al7) and of two computed models (Fig. 2b).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "We", "computed", "average", "fluctuations", "of", "the", "human", "complex", "using", "two", "replicates", "of", "the", "human", "crystal", "complex", "(", "7al7", ")", "and", "of", "two", "computed", "models", "(", "Fig.", "2b", ")", "." ] } ]
PMC10317042
To determine the transcription factors regulating EWSR1::ATF1 promoter activity, we used the FindMotifs tool from Signac.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "To", "determine", "the", "transcription", "factors", "regulating", "EWSR1::ATF1", "promoter", "activity", ",", "we", "used", "the", "FindMotifs", "tool", "from", "Signac", "." ] } ]
PMC11724582
The standard deviation for statistical significance was set at P < 0.05.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "standard", "deviation", "for", "statistical", "significance", "was", "set", "at", "P", "<", "0.05", "." ] } ]
PMC8992508
Compounds 65 and 69 interact with both BCRP and P-gp in fact, a 2-methoxygroup on phenyl tetrazole moiety (R1) leads to a moderate inhibitory activity on P-gp lowering BCRP selectivity (65, IC50 = 11.0 μM on P-gp, IC50 = 0.451 μM on BCRP; 69, IC50 = 7.73 μM on P-gp, IC50 = 0.180 μM on BCRP).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Compounds", "65", "and", "69", "interact", "with", "both", "BCRP", "and", "P-gp", "in", "fact", ",", "a", "2-methoxygroup", "on", "phenyl", "tetrazole", "moiety", "(", "R1", ")", "leads", "to", "a", "moderate", "inhibitory", "activity", "on", "P-gp", "lowering", "BCRP", "selectivity", "(", "65", ",", "IC50", "=", "11.0", "μM", "on", "P-gp", ",", "IC50", "=", "0.451", "μM", "on", "BCRP", ";", "69", ",", "IC50", "=", "7.73", "μM", "on", "P-gp", ",", "IC50", "=", "0.180", "μM", "on", "BCRP", ")", "." ] } ]
PMC6312945
HBV enters the hepatocytes and destroys the DNA in the hepatocytes, causing cirrhosis of the liver and developing into liver cancer (3).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "HBV", "enters", "the", "hepatocytes", "and", "destroys", "the", "DNA", "in", "the", "hepatocytes", ",", "causing", "cirrhosis", "of", "the", "liver", "and", "developing", "into", "liver", "cancer", "(", "3", ")", "." ] } ]
PMC7153288
The Erlenmeyer was shaken at 180 rpm for 5 days.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "Erlenmeyer", "was", "shaken", "at", "180", "rpm", "for", "5", "days", "." ] } ]
PMC10440586
Under hypoxia conditions, CD99 is upregulated and is associated with angiogenesis and metabolic reprogramming.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Under", "hypoxia", "conditions", ",", "CD99", "is", "upregulated", "and", "is", "associated", "with", "angiogenesis", "and", "metabolic", "reprogramming", "." ] } ]
PMC8658661
It should be noted that hepatoblastoma is the most common malignant liver tumor in children; it accounts for about 70% of cases, followed by HCC, accounting for 27% .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "It", "should", "be", "noted", "that", "hepatoblastoma", "is", "the", "most", "common", "malignant", "liver", "tumor", "in", "children", ";", "it", "accounts", "for", "about", "70", "%", "of", "cases", ",", "followed", "by", "HCC", ",", "accounting", "for", "27", "%", "." ] } ]
PMC11741577
Secreted tryptase levels were measured in HMC-1 CM, FSL-1-HMC-1 CM, HaCaT CM, THP-1 CM, and serum-free IMDM using a human tryptase ELISA kit (Innovative Research Inc., Novi, MI, USA) in accordance with the manufacturer’s protocol.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "B-CellLine", "O", "O", "B-CellLine", "O", "O", "B-CellLine", "O", "O", "B-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Secreted", "tryptase", "levels", "were", "measured", "in", "HMC-1", "CM", ",", "FSL-1-HMC-1", "CM", ",", "HaCaT", "CM", ",", "THP-1", "CM", ",", "and", "serum-free", "IMDM", "using", "a", "human", "tryptase", "ELISA", "kit", "(", "Innovative", "Research", "Inc.", ",", "Novi", ",", "MI", ",", "USA", ")", "in", "accordance", "with", "the", "manufacturer", "’s", "protocol", "." ] } ]
PMC11188874
However, co-treatment with the HDAC6 inhibitors suppressed the effects of bortezomib to suggest that HDAC6 inhibitors were not increasing antigen presentation through upregulated autophagy.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "However", ",", "co-treatment", "with", "the", "HDAC6", "inhibitors", "suppressed", "the", "effects", "of", "bortezomib", "to", "suggest", "that", "HDAC6", "inhibitors", "were", "not", "increasing", "antigen", "presentation", "through", "upregulated", "autophagy", "." ] } ]
PMC11566417
Highlighted nodes were selected and “publish_gostplot” was used to generate a Manhattan plot of enriched GO terms in each CM sample.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Highlighted", "nodes", "were", "selected", "and", "“", "publish_gostplot", "”", "was", "used", "to", "generate", "a", "Manhattan", "plot", "of", "enriched", "GO", "terms", "in", "each", "CM", "sample", "." ] } ]
PMC5574817
HEK293 cell line was purchased from American Type Culture Collection (ATCC, USA).
[ { "tags": [ "B-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "HEK293", "cell", "line", "was", "purchased", "from", "American", "Type", "Culture", "Collection", "(", "ATCC", ",", "USA", ")", "." ] } ]
PMC7305184
When 70% confluency was reached, cells were detached by 10x trypsin-EDTA (PAA, Austria), diluted 1:9 in Hank’s basal salt solution (StemCell, Canada) and incubated at 37 °C for 2 minutes.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "When", "70", "%", "confluency", "was", "reached", ",", "cells", "were", "detached", "by", "10x", "trypsin-EDTA", "(", "PAA", ",", "Austria", ")", ",", "diluted", "1:9", "in", "Hank", "’s", "basal", "salt", "solution", "(", "StemCell", ",", "Canada", ")", "and", "incubated", "at", "37", "°", "C", "for", "2", "minutes", "." ] } ]
PMC11750712
Time relative to first AUTO4 treatment.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Time", "relative", "to", "first", "AUTO4", "treatment", "." ] } ]
PMC9429973
An increase in infections and non-relapse related mortality has been reported in patients with IO who underwent hematopoietic cell transplantation (HCT).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "An", "increase", "in", "infections", "and", "non-relapse", "related", "mortality", "has", "been", "reported", "in", "patients", "with", "IO", "who", "underwent", "hematopoietic", "cell", "transplantation", "(", "HCT", ")", "." ] } ]
PMC11354239
The aim of this study was to analyze the gene expression profile of the NK cells involved in the cytolytic response stimulated by rituximab.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "aim", "of", "this", "study", "was", "to", "analyze", "the", "gene", "expression", "profile", "of", "the", "NK", "cells", "involved", "in", "the", "cytolytic", "response", "stimulated", "by", "rituximab", "." ] } ]
PMC9429973
These data are from Gene Expression Omnibus (GEO) datasets.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "These", "data", "are", "from", "Gene", "Expression", "Omnibus", "(", "GEO", ")", "datasets", "." ] } ]
PMC10940855
EPHB4 was also the most highly expressed EPHB receptor in the human BM EC line, BMEC-60 (Supplementary Fig. S2B).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellLine", "O", "O", "O", "O", "O", "O" ], "tokens": [ "EPHB4", "was", "also", "the", "most", "highly", "expressed", "EPHB", "receptor", "in", "the", "human", "BM", "EC", "line", ",", "BMEC-60", "(", "Supplementary", "Fig.", "S2B", ")", "." ] } ]
PMC10976516
For stage II malignancies, platinum-based adjuvant treatment is advised after complete resection.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "For", "stage", "II", "malignancies", ",", "platinum-based", "adjuvant", "treatment", "is", "advised", "after", "complete", "resection", "." ] } ]
PMC11680049
We have previously observed a similar physiological and biosynthetic response to the presence of lighting when working with other representatives of relict gymnosperms—plants of the genus Taxus .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "We", "have", "previously", "observed", "a", "similar", "physiological", "and", "biosynthetic", "response", "to", "the", "presence", "of", "lighting", "when", "working", "with", "other", "representatives", "of", "relict", "gymnosperms", "—", "plants", "of", "the", "genus", "Taxus", "." ] } ]
PMC11789597
The cells were stained with anti‐human CD45‐pacific blue, Annexin V‐APC, and 7‐AAD.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "cells", "were", "stained", "with", "anti‐human", "CD45‐pacific", "blue", ",", "Annexin", "V‐APC", ",", "and", "7‐AAD", "." ] } ]
PMC11544122
Endocytosis of each phospho-cluster variant was reduced relative to WT CXCR4 (Fig. 5b), indicating the importance of both phospho-clusters for CXCR4 endocytosis.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Endocytosis", "of", "each", "phospho-cluster", "variant", "was", "reduced", "relative", "to", "WT", "CXCR4", "(", "Fig.", "5b", ")", ",", "indicating", "the", "importance", "of", "both", "phospho-clusters", "for", "CXCR4", "endocytosis", "." ] } ]
PMC10988555
To further understand what is triggering this cell death and loss of viability by the presence of the cobalt complexes, intracellular reactive oxygen species (ROS) were measured.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "To", "further", "understand", "what", "is", "triggering", "this", "cell", "death", "and", "loss", "of", "viability", "by", "the", "presence", "of", "the", "cobalt", "complexes", ",", "intracellular", "reactive", "oxygen", "species", "(", "ROS", ")", "were", "measured", "." ] } ]
PMC11736898
D3 is metabolized to 25-hydroxy vitamin D (25(OH)D), the form most commonly measured in the blood as a marker of vitamin D status, by CYP27A1.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "D3", "is", "metabolized", "to", "25-hydroxy", "vitamin", "D", "(", "25(OH)D", ")", ",", "the", "form", "most", "commonly", "measured", "in", "the", "blood", "as", "a", "marker", "of", "vitamin", "D", "status", ",", "by", "CYP27A1", "." ] } ]
PMC11481779
The first ones relied on epigenetic signals (e.g. ChIP-Seqs, or ATAC-Seqs) or peaks [4–7].
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "first", "ones", "relied", "on", "epigenetic", "signals", "(", "e.g.", "ChIP-Seqs", ",", "or", "ATAC-Seqs", ")", "or", "peaks", "[", "4–7", "]", "." ] } ]
PMC11549062
The PTP1B‐Rab5‐PDGFR‐β axis appears to play a pivotal role in this biological regulation.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "PTP1B‐Rab5‐PDGFR‐β", "axis", "appears", "to", "play", "a", "pivotal", "role", "in", "this", "biological", "regulation", "." ] } ]
PMC11507371
Once translocated into the nucleus, Keap1 binds to Nrf2 and dissociates it from ARE.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Once", "translocated", "into", "the", "nucleus", ",", "Keap1", "binds", "to", "Nrf2", "and", "dissociates", "it", "from", "ARE", "." ] } ]
PMC6684588
Scale bar, 100 µm. (
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Scale", "bar", ",", "100", "µm", ".", "(" ] } ]
PMC10994876
The Mock group exhibited a mean percentage of apoptotic cells of 7.27% ± 1.13% (mean ± SD), while the NT group showed a mean percentage of apoptotic cells of 5.83% ± 1.12% (mean ± SD).
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "The", "Mock", "group", "exhibited", "a", "mean", "percentage", "of", "apoptotic", "cells", "of", "7.27", "%", "±", "1.13", "%", "(", "mean", "±", "SD", ")", ",", "while", "the", "NT", "group", "showed", "a", "mean", "percentage", "of", "apoptotic", "cells", "of", "5.83", "%", "±", "1.12", "%", "(", "mean", "±", "SD", ")", "." ] } ]
PMC11243198
Subsequent to our initial similarity search, it was reported that the active form of GANT61 was a diamine derivative (termed GANT61-D) resulting from the hydrolysis of the parent compound .
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Subsequent", "to", "our", "initial", "similarity", "search", ",", "it", "was", "reported", "that", "the", "active", "form", "of", "GANT61", "was", "a", "diamine", "derivative", "(", "termed", "GANT61-D", ")", "resulting", "from", "the", "hydrolysis", "of", "the", "parent", "compound", "." ] } ]
PMC9429973
Proof of prinicple was performed using the residual peaks covering the MFI range provided by the beads.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "Proof", "of", "prinicple", "was", "performed", "using", "the", "residual", "peaks", "covering", "the", "MFI", "range", "provided", "by", "the", "beads", "." ] } ]
PMC11412721
ACKR4 is not a prognostic factor in Multiple Myeloma.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "ACKR4", "is", "not", "a", "prognostic", "factor", "in", "Multiple", "Myeloma", "." ] } ]
PMC11438317
B Activation of a luciferase reporter gene driven by the IL-2 minimal promoter in Jurkat cells transfected with rac-QL, a dominant active mutant of rac, and LYP and and stimulated with CD3 plus CD28 antibodies for 6 h. The insert shows the IB of LYP. *
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CellLine", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "B", "Activation", "of", "a", "luciferase", "reporter", "gene", "driven", "by", "the", "IL-2", "minimal", "promoter", "in", "Jurkat", "cells", "transfected", "with", "rac-QL", ",", "a", "dominant", "active", "mutant", "of", "rac", ",", "and", "LYP", "and", "and", "stimulated", "with", "CD3", "plus", "CD28", "antibodies", "for", "6", "h.", "The", "insert", "shows", "the", "IB", "of", "LYP", ".", "*" ] } ]
PMC9261184
These GWP values reflect the IPCC fifth assessment report including indirect warming effects.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "These", "GWP", "values", "reflect", "the", "IPCC", "fifth", "assessment", "report", "including", "indirect", "warming", "effects", "." ] } ]
PMC11468365
This indicates that the consistency of MultiComb can be acceptable.
[ { "tags": [ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ], "tokens": [ "This", "indicates", "that", "the", "consistency", "of", "MultiComb", "can", "be", "acceptable", "." ] } ]